PMCB vs. APTO, AIM, NSTGQ, EVAX, SNTI, ZIVO, COEP, IKT, BCDA, and PLUR
Should you be buying PharmaCyte Biotech stock or one of its competitors? The main competitors of PharmaCyte Biotech include Aptose Biosciences (APTO), AIM ImmunoTech (AIM), NanoString Technologies (NSTGQ), Evaxion Biotech A/S (EVAX), Senti Biosciences (SNTI), ZIVO Bioscience (ZIVO), Coeptis Therapeutics (COEP), Inhibikase Therapeutics (IKT), BioCardia (BCDA), and Pluri (PLUR). These companies are all part of the "biological products, except diagnostic" industry.
Aptose Biosciences (NASDAQ:APTO) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
Aptose Biosciences received 375 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users.
PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Aptose Biosciences' return on equity of -9.69% beat PharmaCyte Biotech's return on equity.
26.6% of Aptose Biosciences shares are held by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are held by institutional investors. 9.5% of Aptose Biosciences shares are held by insiders. Comparatively, 1.0% of PharmaCyte Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Aptose Biosciences had 1 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 2 mentions for Aptose Biosciences and 1 mentions for PharmaCyte Biotech. Aptose Biosciences' average media sentiment score of 1.00 beat PharmaCyte Biotech's score of 0.50 indicating that PharmaCyte Biotech is being referred to more favorably in the news media.
Aptose Biosciences has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.18, meaning that its share price is 118% less volatile than the S&P 500.
Aptose Biosciences presently has a consensus target price of $19.80, indicating a potential upside of 1,522.95%. Given PharmaCyte Biotech's higher possible upside, equities research analysts clearly believe Aptose Biosciences is more favorable than PharmaCyte Biotech.
Summary
Aptose Biosciences beats PharmaCyte Biotech on 7 of the 13 factors compared between the two stocks.
Get PharmaCyte Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PharmaCyte Biotech Competitors List
Related Companies and Tools
